Vanguard Capital Management
MCRB icon

Vanguard Capital Management’s Seres Therapeutics MCRB Stock Holding History

Vanguard Capital Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.27M Sell
287,776
-6,367
-2% -$48.5K ﹤0.01% 3383
2026
Q1 		$2.61M Buy
+294,143
New +$3.44M ﹤0.01% 3271

Other funds holding MCRB

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management's MCRB Position: Q2 2026 in Review

Vanguard Capital Management reduced its Seres Therapeutics (MCRB) stake by 2.2% in Q2 2026, selling an estimated $48.5K and leaving 287,776 shares worth $2.27M. The position accounts for ﹤0.01% of the portfolio, ranked #3383.

Vanguard Capital Management first reported a position in MCRB in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.61M in Q1 2026. 35 funds tracked by Wall St. Rank hold MCRB as of Q2 2026.

  • Vanguard Capital Management held 287,776 shares of Seres Therapeutics worth $2.27M as of Q2 2026.
  • Vanguard Capital Management sold 6,367 Seres Therapeutics shares in Q2 2026, an estimated $48.5K.
  • Seres Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3383 holding.
  • Vanguard Capital Management first reported a position in Seres Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Seres Therapeutics position peaked at $2.61M in Q1 2026.
  • 35 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.